Star Bulk Carriers Corp. (SBLK)
NASDAQ: SBLK · Real-Time Price · USD
19.15
-0.16 (-0.83%)
At close: Aug 6, 2025, 4:00 PM
19.00
-0.15 (-0.78%)
After-hours: Aug 6, 2025, 7:54 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Revance Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $22.67, which forecasts a 18.38% increase in the stock price over the next year. The lowest target is $21 and the highest is $26.
Price Target: $22.67 (+18.38%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 19, 2025.
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Maintains $22 → $21 | Strong Buy | Maintains | $22 → $21 | +9.66% | Feb 19, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $28 | Strong Buy | Maintains | $28 | +46.21% | Nov 20, 2024 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $30 → $21 | Strong Buy → Hold | Downgrades | $30 → $21 | +9.66% | Oct 23, 2024 |
| Deutsche Bank | Deutsche Bank | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +35.77% | Sep 4, 2024 |
| Stifel | Stifel | Strong Buy Maintains $28 → $30 | Strong Buy | Maintains | $28 → $30 | +56.66% | May 24, 2024 |
Financial Forecast
Revenue This Year
997.48M
from 1.27B
Decreased by -21.18%
Revenue Next Year
1.15B
from 997.48M
Increased by 15.19%
EPS This Year
1.74
from 2.80
Decreased by -37.83%
EPS Next Year
2.99
from 1.74
Increased by 71.68%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.3B | 1.5B | 1.3B |
| Avg | 997.5M | 1.1B | 1.1B |
| Low | 761.7M | 959.0M | 965.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.7% | 46.4% | 10.0% |
| Avg | -21.2% | 15.2% | -1.5% |
| Low | -39.8% | -3.9% | -16.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.33 | 4.31 | 4.44 |
| Avg | 1.74 | 2.99 | 3.83 |
| Low | 1.23 | 1.80 | 2.86 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -16.7% | 147.3% | 48.6% |
| Avg | -37.8% | 71.7% | 28.0% |
| Low | -55.9% | 3.6% | -4.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.